『Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals』のカバーアート

Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals

Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals

著者： Fexingo
無料で聴く

Lucas and Luna step into the clean, cool world of biotechnology startups, where drug discovery meets the harsh realities of FDA approvals and venture capital. Each episode takes a single biotech company—from Moderna to a tiny CRISPR spinout—and dissects its science, its business model, and the regulatory path that determines its fate. Lucas brings the numbers: clinical trial phases, patent cliffs, burn rates. Luna presses on the human stories: the researchers betting careers on a single molecule, the patients waiting for therapies that might never come. They don't celebrate hype; they ask whether the science holds up, whether the market exists, and whether the FDA will say yes. Listeners will walk away able to read a biotech 10-K, understand a Phase II readout, and spot the difference between a genuine breakthrough and a stock promotion. How do you value a company with no revenue and a 90% chance of failure? #Biotech #Lifesciences #DrugDiscovery #FDAApprovals #ClinicalTrials #Startups #VentureCapital #Pharma #Genomics #CRISPR #Therapeutics #RegulatoryScience #Patents #Investment #Business #FexingoBusiness #BusinessPodcast #Technology Keep every episode free: buymeacoffee.com/fexingo© 2026 Fexingo. All rights reserved. 経済学
エピソード
  • The Biotech Supply Chain Bottleneck

    The Biotech Supply Chain Bottleneck
    2026/09/10
    In this episode of Biotech Business, Lucas and Luna dissect the hidden crisis in life sciences: the critical shortage of single-use bioreactor bags. With global demand outpacing supply, startups are facing lead times of up to six months for essential consumables. We explore how companies like Sartorius and Merck KGaA are expanding capacity, why secondary suppliers are struggling with quality control, and what this means for drug development pipelines in late 2026. The conversation also covers the strategic shift toward vertical integration among mid-tier manufacturers and the financial implications of holding excess inventory during a valuation winter. #BiotechSupplyChain #SingleUseBags #LifeSciencesManufacturing #DrugDevelopment #Sartorius #MerckKGAa #VentureDebt #FDAApprovals #BioPharmaOperations #FexingoBusiness #BusinessPodcast #StartupStrategy #SupplyChainResilience #Bioprocessing #LabEquipment #GlobalHealthcare #OperationalRisk #InvestorRelations Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    11 分
  • How Biotech Startups Are Solving The Protein Degradation Problem

    How Biotech Startups Are Solving The Protein Degradation Problem
    2026/09/09
    We dive into the mechanics and economics of molecular glues and PROTACs, exploring how startups are moving beyond traditional small molecules to selectively tag proteins for destruction. We look at specific clinical progress in targeting previously undruggable disease drivers, the unique manufacturing hurdles of complex biologics, and why this technology is reshaping venture capital valuations in late-stage biotech as of September 2026. #BiotechStartups #DrugDiscovery #ProteinDegraders #MolecularGlues #PROTACs #UndruggableTargets #VentureCapital #FDAApprovals #LifeSciences #BusinessTechnology #FexingoBusiness #BusinessPodcast #LucasAndLuna #PharmaInnovation #ClinicalTrials #DeepTech #HealthcareInvesting #PrecisionMedicine Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    12 分
  • Biotech Startups Navigating The Valuation Winter

    Biotech Startups Navigating The Valuation Winter
    2026/09/08
    In this episode of Biotech Business, Lucas and Luna dissect the structural shift in life sciences financing as September 2026 arrives. With venture capital drying up for early-stage discovery, startups are pivoting from speculative moonshots to asset-light partnerships and strategic mergers. We examine how companies like Gilead Sciences and Merck are acquiring promising pipelines instead of funding them from scratch, and what this means for the future of independent biotech innovation. Listeners will learn why the traditional IPO window is closed for most and how founder-friendly structures are replacing pure equity plays. #BiotechBusiness #FexingoBusiness #LifeSciences #VentureCapital #DrugDiscovery #FDAApprovals #MergersAndAcquisitions #BiotechStartups #PharmaBigFive #ValuationWinter #AssetLight #StrategicPartnerships #ClinicalTrials #GileadSciences #MerckAndCo #HealthcareInvesting #StartupStrategy #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    10 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません